Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Position Decreased by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,086 shares of the company’s stock after selling 1,712 shares during the quarter. Russell Investments Group Ltd.’s holdings in Syndax Pharmaceuticals were worth $369,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Teacher Retirement System of Texas boosted its stake in shares of Syndax Pharmaceuticals by 5.1% during the 3rd quarter. Teacher Retirement System of Texas now owns 15,619 shares of the company’s stock worth $227,000 after acquiring an additional 757 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Syndax Pharmaceuticals by 5.3% during the 4th quarter. Arizona State Retirement System now owns 16,511 shares of the company’s stock worth $357,000 after acquiring an additional 835 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Syndax Pharmaceuticals by 3.6% in the third quarter. New York State Common Retirement Fund now owns 30,825 shares of the company’s stock worth $448,000 after buying an additional 1,080 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Syndax Pharmaceuticals by 9.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,126 shares of the company’s stock worth $305,000 after buying an additional 1,162 shares during the period. Finally, CWM LLC boosted its position in shares of Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after buying an additional 1,358 shares during the period.

Analysts Set New Price Targets

Several brokerages have recently commented on SNDX. HC Wainwright reaffirmed a “buy” rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research report on Thursday, May 9th. Stifel Nicolaus raised their target price on Syndax Pharmaceuticals from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $34.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday. Citigroup cut their price objective on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Finally, Scotiabank lowered Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and cut their price objective for the stock from $36.00 to $23.00 in a report on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $34.42.

Check Out Our Latest Stock Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX opened at $20.76 on Thursday. The stock’s 50-day moving average is $22.03 and its two-hundred day moving average is $20.72. The firm has a market cap of $1.76 billion, a P/E ratio of -6.45 and a beta of 1.01. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $11.22 and a fifty-two week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.11. During the same period in the prior year, the business earned ($0.59) earnings per share. On average, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -3.58 EPS for the current year.

Syndax Pharmaceuticals Profile

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Further Reading

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.